Browse drugs

…ain—ranibizumab, aflibercept (2 mg and 8 mg), brolucizumab, and faricimab—each differing in dosing interval, mechanism, and cost. Compara…

… and biosimilar ranibizumab, aflibercept 2 mg, brolucizumab and faricimab—across three dosing regimens: fixed, Pro Re Nata and Treat-and-…

…ltiple anti-VEGF agents, including ranibizumab, aflibercept and faricimab, over 19 months. Despite ongoing therapy, her SRF persisted and…

…otal of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), fol…

…III randomised controlled trials (RCTs) evaluating ranibizumab, brolucizumab, aflibercept, and faricimab in nAMD. Baseline characteristics i…

…tion therapy with anti-VEGF agents (aflibercept, bevacizumab or faricimab) and one eye received three treatments.The average number of ad…

…f aflibercept 8 mg (AFL-8) compared to faricimab 6 mg (FAR) and aflibercept 2 mg (AFL-2).Material and Methods Clinical trial data of phase …

…th IMU. Among 117 drugs with positive signals for IMU in FAERS, brolucizumab (ROR 025=145.89, IC025=7.08), faricimab (ROR025=134.06, IC025=6…

…ms This study aimed to investigate the outcomes of intravitreal faricimab (IVF) injection for neovascular age-related macular degeneratio…